Sideras et al. found that 79% HCC patients had Gal-9 expression, while Gal-9 mainly expressed in tumor cells, they also found that low Gal-9 and PD-L1 expression level and low number of CD8+ tumor-infiltrating lymphocyte (TILs) were associated with reduced outcome in HCC [15]. This evidence concerns the gene CD8A and hepatocellular carcinoma.